Hemophilia A Drugs Market Segmentation By Product (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Antifibrinolytics, Desmopressin and Others); By Route of Administration (Intravenous, Oral, Nasal and Others); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) - Global Demand Analysis & Opportunity Outlook 2028

  • Report ID: 2422
  • Published Date: Feb 09, 2023
  • Report Format: PDF, PPT

Introduction to Hemophilia A Drugs

Hemophilia is a condition in which the body is not able to form blood clots in order to stop bleeding. In a normal person’s body, the blood contains certain chemical substances which create a clot in case of bleeding. However, when a person has hemophilia, some clotting factors are absent which leads to the body being unable to form any clot. This result in continuous bleeding and eventually, severe loss of blood.

Hemophilia A is a rare genetic disorder of the blood characterized by a deficiency in the production of plasma protein factor VIII, which results in a reduced clotting property of the blood. Hemophilia drugs are given to hemophilic patients in order to provide them with these clotting factors artificially.

Market Size and Forecast

The hemophilia A drugs market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by product, by route of administration, by distribution channel and by region, out of which, the product segment is further segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, antifibrinolytics, desmopressin and others. The segment for plasma derived coagulation factors is anticipated to hold the largest share in the hemophilia A drugs market on account of highest usage as compared with other products. Plasma derives coagulation factors further can be segmented into factors such as factor VIII, factor IX, factor XIII, von Willebrand factor and active prothrombin complex concentrates. As a result of this, the segment accounts for the highest share in the market. The segment for route of administration is further segmented into intravenous, oral, nasal and others, out of which, the intravenous segment currently holds the largest share in the market. Since the majority of Hemophilia A drugs are in the form of injectable drugs, the market share of this route of administration is high. Moreover, administration of the drug directly into the blood is preferred over other routes. The segment for distribution channel is segmented into hospital pharmacy, retail pharmacy and online pharmacy. The segment for retail pharmacy is predicted to hold the leading share in the market as a result of growing preference of people for buying medicines are the pharmacies near their homes. On the other hand, the online pharmacy segment is anticipated to witness the highest growth rate on account of increasing demand of buying products online as ease of convenience of buying medications through online portals and having them delivered at home.

Growth Drivers

Rising Instances of Genetic Disorders to Boost the Market Growth

The cases of genetic disorders such as hemophilia have been growing significantly in the past few years and are estimated to grow further in the coming years. According to the National Hemophilia Foundation, Hemophilia A occurs in 1 out of 5,000 live male births in the United States. Additionally, hemophilia A is four times more common than hemophilia B. About 20,000 people in the United States are estimated to have hemophilia. Globally, around 400,000 people are predicted to be hemophilic. The report mentioned that approximately 75% of people with hemophilia do not receive proper treatment. On the back of these statistics, the market for hemophilia A drugs is anticipated to grow over the forecast period. 


High Cost of Treatment for Hemophilia A to Restrict the Market Growth

The high costs associated with the drugs as well as the therapies available for hemophilia A treatment is predicted to make them unaffordable for a large section of the society, specially people belonging to the low and middle income countries. On the basis of this factor, the hemophilia A drugs market is estimated to observe limited growth in coming years.

Market Segmentation

Our in-depth analysis of the hemophilia A drugs market includes the following segments:

By Product

  • Plasma Derived Coagulation Factor Concentrate
  • Recombinant Coagulation Factor Concentrates
  • Antifibrinolytics
  • Desmopressin 
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Nasal
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

On the basis of regional analysis, the hemophilia A drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Hemophilia A drugs market in North America is projected to hold the leading share in the market. This can be attributed to the recent advancements in the healthcare industry as well as the research and development of new drugs. Moreover, increased drug approvals further contribute towards the growth of market in this region. The market in Asia Pacific, however, is estimated to observe the highest growth rate over the forecast period as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia in the region.

Hemophilia A Drugs Market

The hemophilia A drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market


In the News

  • On April 1, 2020, the U.S. Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw], a drug containing a recombinant analog of human FVII as the active ingredient, for the treatment as well as control of bleeding in people above the age of 12 with hemophilia A or B.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2422
  • Published Date: Feb 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of hemophilia A and growing awareness among people about the requirement for effective drugs for treatment are major factors driving the market growth.

The market is anticipated to attain a significant CAGR over the forecast period, i.e. 2020-2028.

Asia Pacific is estimated to provide more business opportunities for growth as a result of rising number of patients with hemophilia A and growing awareness about the need for preventing and treating hemophilia.

The major players in the market are Pfizer Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Genzyme Corporation, Grifols, S.A., CSL Behring, Octapharma AG, Aptevo Therapeutics and Ferring Pharmaceuticals.

Company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying